Medscape Transplantation Podcast

Drs Lisa VanWagner and Kathleen Corey examine how MASLD should shape cardiovascular risk assessment, statin use, and treatment decisions.

Dr Benjamin Levy III reviews how to recognize, evaluate, and manage colitis and other GI complications that can arise with immune checkpoint inhibitors.

Listener feedback on the nonobstructive HCM trials, AI-enhanced visits, timing of non-culprit PCI in STEMI, new tricuspid valve intervention, and EP at a crossroads are the topics John Mandrola, MD, discusses in this week’s podcast.

A preview of ACR 2026 updates in SLE and lupus nephritis, spanning emerging therapies, kidney biopsy findings, cardiovascular risk management, and individualized dosing.

Key findings from HFSA 2026, including emerging diagnostic imaging, health status and cardiac biomarker findings, and initiatives to improve disease recognition and management.

Dr Jeffrey Turner spotlights advances in CKD therapy implementation, emerging treatments, xenotransplantation, and the responsible use of AI in nephrology.

Dr Mazen Noureddin explains how PCPs can identify MASH patients with fibrosis who may benefit from liver-directed therapy, while maintaining lifestyle and metabolic care.

Two new AGA updates reshape how clinicians test for, treat, and prevent recurrent C difficile, including tailored guidance for patients with IBD.

Drs Alexander and Urey walk through stabilizers vs silencers, pivotal trial data, and practical first line choices to help you select the right ATTR CM therapy for each patient.

When fatty liver appears incidentally on imaging, "just lose weight" isn't enough. Dr Brandman explains how to use FIB-4, FibroScan, and ELF to triage who needs referral and who doesn't.